Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors
Debashis Sarker(King's College - North Carolina), Udai Banerji(Institute of Cancer Research), Rupert Dixon(UCB Pharma (United Kingdom)), Joanne Mann(UCB Pharma (United Kingdom)), Leonidas Mavroeidis(University of Oxford), Ruth Plummer(National Health Service), Elodie Garric(UCB Pharma (Belgium)), Sarah P. Blagden(Churchill Hospital), Natalie Cook(Manchester Academic Health Science Centre), Ivan Matthews(UCB Pharma (United Kingdom)), Angelos Angelakas(The Christie NHS Foundation Trust), S. El Badri(University of Oxford), Abdul Muhith(King's College London), Saira Bashir(Newcastle University), Mark White(Beatson West of Scotland Cancer Centre), T.R. Jeff Evans(Beatson West of Scotland Cancer Centre), Cienne Morton(Guy's and St Thomas' NHS Foundation Trust)
Cited by 6
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406